InvestorsObserver

BMY Bristol-Myers Squibb Company

$54.23 $0.98 (1.84%)
15 Minute Delayed Price Enable Real-Time Price
Overall

BMY Stock Analysis Overview

What this means: InvestorsObserver gives Bristol-Myers Squibb Company (BMY) an overall rank of 39, which is below average. Bristol-Myers Squibb Company is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 39 means that 61% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

BMY Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

BMY Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

BMY Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

BMY Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

BMY Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

BMY Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

BMY Stock Analysis Overview

What this means: InvestorsObserver gives Bristol-Myers Squibb Company (BMY) an overall rank of 39, which is below average. Bristol-Myers Squibb Company is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 39 means that 61% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full BMY report

BMY Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

BMY Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

BMY Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

BMY Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

BMY Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

BMY Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Bristol-Myers Squibb Company (BMY) Analyst Forecast

BMY Price, Volume, Earnings, and Dividend Date

  • Last Price $54.23
  • Previous Close $53.25
  • Change $0.98
  • Open $53.39
  • Volume 13,432,613
  • Avg. Volume (100-day) 16,162,622
  • Market Cap 109,663,548,679
  • Days Range 53.39 - 54.475
  • 52-week Range 47.58 - 71.07
  • Dividend Yield 4.51%
  • Ex. Dividend Date 04/04/24
  • P-E 13.42
  • EPS 3.86
  • Earnings Date 04/25/24
  • Sector Healthcare
  • Industry Drug Manufacturers - General
  • Avg. Analyst Rec. Premium
  • Beta -0.134
  • PEG Ratio 1.58

Bristol-Myers Squibb Company (BMY) Company Description

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

Bristol-Myers Squibb Company (BMY) Stock Chart